Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

(Bloomberg) -- Wegovy, the blockbuster weight-loss medication from Novo Nordisk A/S, eased heart failure symptoms for patients with diabetes in the latest large trial to support use of the drug to ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.